Used in pharmaceutical research as a key intermediate in the synthesis of potent PARP (poly ADP-ribose polymerase) inhibitors. It plays a critical role in developing anticancer agents, particularly for treating tumors with deficiencies in DNA repair pathways, such as BRCA-mutated breast and ovarian cancers. The compound’s structure enables strong binding to the PARP enzyme, enhancing the efficacy of chemotherapy by preventing cancer cells from repairing DNA damage. It is also explored in targeted therapy research due to its selectivity and potency in cellular assays.